{
    "ticker": "VSTM",
    "name": "Verastem, Inc.",
    "description": "Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with cancer. Founded in 2010 and headquartered in Needham, Massachusetts, Verastem is committed to advancing novel treatment options for hematologic and solid tumors. The company's lead product candidate is duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which is approved for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). Verastem is also exploring additional product candidates in its pipeline, including VS-6766, a novel RAS/MEK pathway inhibitor, aimed at treating a variety of cancers. The company works diligently to understand the underlying biology of cancer to create effective therapies that address unmet medical needs. With a strong emphasis on scientific innovation and patient-centric approaches, Verastem strives to improve outcomes for cancer patients and contribute to the evolving landscape of oncology treatment.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Needham, Massachusetts, USA",
    "founded": "2010",
    "website": "https://www.verastem.com",
    "ceo": "Robert Forrester",
    "social_media": {
        "twitter": "https://twitter.com/Verastem",
        "linkedin": "https://www.linkedin.com/company/verastem-inc/"
    },
    "investor_relations": "https://investors.verastem.com",
    "key_executives": [
        {
            "name": "Robert Forrester",
            "position": "CEO"
        },
        {
            "name": "Andrew Johns",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "Duvelisib",
                "VS-6766"
            ]
        }
    ],
    "seo": {
        "meta_title": "Verastem, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Verastem, Inc., a biopharmaceutical company dedicated to developing innovative therapies for cancer patients. Discover our product pipeline and commitment to oncology.",
        "keywords": [
            "Verastem",
            "Cancer Therapies",
            "Duvelisib",
            "Biopharmaceuticals",
            "Oncology",
            "Cancer Treatment"
        ]
    },
    "faq": [
        {
            "question": "What is Verastem known for?",
            "answer": "Verastem is known for developing innovative cancer therapies, particularly duvelisib for CLL and FL."
        },
        {
            "question": "Who is the CEO of Verastem?",
            "answer": "Robert Forrester is the CEO of Verastem, Inc."
        },
        {
            "question": "Where is Verastem headquartered?",
            "answer": "Verastem is headquartered in Needham, Massachusetts, USA."
        },
        {
            "question": "What are Verastem's main products?",
            "answer": "Verastem's main products include duvelisib and VS-6766."
        },
        {
            "question": "When was Verastem founded?",
            "answer": "Verastem was founded in 2010."
        }
    ],
    "competitors": [
        "CLVS",
        "KPTI",
        "IMMU",
        "BMY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}